BRL-301

BIOLOGICAL3 trials

Sponsors

Bioray Laboratories

Conditions

ANCA Associated Systemic VasculitisAntiphospholipid SyndromeInflammatory MyopathyNon-hodgkin Lymphoma,B CellSjogren's SyndromeSystemic Lupus Erythematosus (SLE)Systemic Sclerosis

Unknown Phase

Universal CAR-T Cells (BRL-301) in Relapse or Refractory Autoimmune Diseases

Enrolling by invitationNCT05859997

Bioray LaboratoriesANCA Associated Systemic Vasculitis, Antiphospholipid Syndrome, Inflammatory Myopathy +3

Start: 2023-05-17End: 2025-05-27Target: 15Updated: 2024-11-20

Universal CAR-T Cells (BRL-301) in Refractory Systemic Lupus Erythematosus

RecruitingNCT05988216

Bioray LaboratoriesSystemic Lupus Erythematosus (SLE)

Start: 2023-08-14End: 2025-09-30Target: 12Updated: 2024-09-27

Universal CAR-T Cell Therapy for NHL

RecruitingNCT07248163

Bioray LaboratoriesNon-hodgkin Lymphoma,B Cell

Start: 2025-03-11End: 2028-03-11Target: 6Updated: 2025-11-25

Related Papers

Allogeneic CD19-targeted CAR-T therapy in refractory systemic lupus erythematosus achieved durable remission.

2025-05-295 citations

Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis.

2024-07-15148 citations